Skip to content
Gemifloxacin
Factive (gemifloxacin) is a small molecule pharmaceutical. Gemifloxacin was first approved as Factive on 2003-04-04. It is used to treat bacterial infections, bronchitis, community-acquired infections, gram-negative bacterial infections, and pneumococcal pneumonia amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
urogenital diseasesD000091642
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gemifloxacin mesylate
Tradename
Company
Number
Date
Products
FACTIVELG ChemN-021158 DISCN2003-04-04
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
factiveNew Drug Application2016-08-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infections—D001424A49
bronchitis—D001991J40
community-acquired infections—D017714—
gram-negative bacterial infections—D016905—
pneumococcal pneumoniaEFO_1001474D011018J13
protozoan infections—D011528B50-B64
urinary tract infectionsEFO_0003103D014552N39.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01M: Quinolone antibacterials
— J01MA: Fluoroquinolone antibacterials, systemic
— J01MA15: Gemifloxacin
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGEMIFLOXACIN
INNgemifloxacin
Description
Gemifloxacin is a 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position. It has a role as a topoisomerase IV inhibitor, an antimicrobial agent and an antibacterial drug. It is a monocarboxylic acid, a 1,8-naphthyridine derivative, a quinolone antibiotic and a fluoroquinolone antibiotic.
Classification
Small molecule
Drug classantibacterials (quinolone derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CO/N=C1\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1CN
Identifiers
PDB—
CAS-ID175463-14-6
RxCUI138099
ChEMBL IDCHEMBL430
ChEBI ID101853
PubChem CID9571107
DrugBankDB01155
UNII IDOKR68Y0E4T (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,447 documents
View more details
Safety
Black-box Warning
Black-box warning for: Factive
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
15 adverse events reported
View more details